Rogelio Lopez-Velez1, Jose-Maria Bayas. 1. Tropical Medicine and Clinical Parasitology, Infectious Diseases Department, Hospital Ramón y Cajal, Madrid, Spain. rlopezvelez.hrc@salud.madrid.org
Abstract
OBJECTIVE: To evaluate travel health knowledge, attitudes, and practices on vaccination and malaria prevention among Spanish travelers to the tropics. METHODS: A cross-sectional survey was carried out in the departure lounge of the two main Spanish international airports in the summer of 2004. A questionnaire was administered to 1,206 Spanish citizens traveling to high-risk areas of tropical South America, 635 travelers (52.6%); Southeast Asia, 251 (20.8%); Sub-Saharan Africa, 181 (15.0%), and the Indian subcontinent, 139 (11.6%). Risk areas were defined according to published sources. Travelers were asked about their attitudes to travel vaccines and malaria prophylaxis and whether they had received either or both on this or previous trips. Adequate malaria prophylaxis was considered as the correct drugs for the destination as indicated by the World Health Organization. RESULTS: Fifty-eight percent of travelers were male and the mean age was 38 years. Thirty-six percent were traveling to tropical areas for the first time. The main reason for travel was tourism (82%) or business (12%). The mean time preparing the trip was 39 days; 73% looked for information a mean of 19 days in advance and 54% were advised in travelers' clinics. Fifty-five percent received no travel vaccines. A total of 48.1% of tourists and 30.1% of business travelers were vaccinated (p<0.00006). The most frequent vaccines administered were as follows: typhoid fever, 32%; yellow fever, 29%; tetanus-diphtheria, 24%; and hepatitis A, 14%. Malaria prophylaxis was taken by 422 travelers including mefloquine (44%), atovaquone-proguanil (17%), chloroquine (16%), chloroquine-proguanil (15%), doxycycline (3%), and unknown (5%). CONCLUSIONS: More than half of travelers to risk areas received no vaccinations before the trip. More than a third of travelers to Sub-Saharan Africa received no malaria prophylaxis.
OBJECTIVE: To evaluate travel health knowledge, attitudes, and practices on vaccination and malaria prevention among Spanish travelers to the tropics. METHODS: A cross-sectional survey was carried out in the departure lounge of the two main Spanish international airports in the summer of 2004. A questionnaire was administered to 1,206 Spanish citizens traveling to high-risk areas of tropical South America, 635 travelers (52.6%); Southeast Asia, 251 (20.8%); Sub-Saharan Africa, 181 (15.0%), and the Indian subcontinent, 139 (11.6%). Risk areas were defined according to published sources. Travelers were asked about their attitudes to travel vaccines and malaria prophylaxis and whether they had received either or both on this or previous trips. Adequate malaria prophylaxis was considered as the correct drugs for the destination as indicated by the World Health Organization. RESULTS: Fifty-eight percent of travelers were male and the mean age was 38 years. Thirty-six percent were traveling to tropical areas for the first time. The main reason for travel was tourism (82%) or business (12%). The mean time preparing the trip was 39 days; 73% looked for information a mean of 19 days in advance and 54% were advised in travelers' clinics. Fifty-five percent received no travel vaccines. A total of 48.1% of tourists and 30.1% of business travelers were vaccinated (p<0.00006). The most frequent vaccines administered were as follows: typhoid fever, 32%; yellow fever, 29%; tetanus-diphtheria, 24%; and hepatitis A, 14%. Malaria prophylaxis was taken by 422 travelers including mefloquine (44%), atovaquone-proguanil (17%), chloroquine (16%), chloroquine-proguanil (15%), doxycycline (3%), and unknown (5%). CONCLUSIONS: More than half of travelers to risk areas received no vaccinations before the trip. More than a third of travelers to Sub-Saharan Africa received no malaria prophylaxis.
Authors: Marc Mendelson; Xiaohong M Davis; Mogens Jensenius; Jay S Keystone; Frank von Sonnenburg; Devon C Hale; Gerd-Dieter Burchard; Vanessa Field; Peter Vincent; David O Freedman Journal: Am J Trop Med Hyg Date: 2010-06 Impact factor: 2.345
Authors: Michael P Muehlenbein; Leigh Ann Martinez; Andrea A Lemke; Laurentius Ambu; Senthilvel Nathan; Sylvia Alsisto; Patrick Andau; Rosman Sakong Journal: Ecohealth Date: 2008-09-23 Impact factor: 3.184
Authors: Anita E Heywood; Rochelle E Watkins; Sopon Iamsirithaworn; Kessarawan Nilvarangkul; C Raina MacIntyre Journal: BMC Public Health Date: 2012-05-02 Impact factor: 3.295
Authors: Jakrapun Pupaibool; Hemantha Walaliyadda; Benjamin Tasevac; Ben J Brintz; In Kyu Park; Michael Graves; L Scott Benson; Peter Hale; Justin Powell; Daniel T Leung Journal: Am J Trop Med Hyg Date: 2021-09-27 Impact factor: 3.707
Authors: Marc Mendelson; Pauline V Han; Peter Vincent; Frank von Sonnenburg; Jakob P Cramer; Louis Loutan; Kevin C Kain; Philippe Parola; Stefan Hagmann; Effrossyni Gkrania-Klotsas; Mark Sotir; Patricia Schlagenhauf Journal: Emerg Infect Dis Date: 2014-04 Impact factor: 6.883
Authors: Rosa López-Gigosos; Magda Campins; María J Calvo; Santiago Pérez-Hoyos; Javier Díez-Domingo; Luis Salleras; María T Azuara; Xavier Martínez; José M Bayas; Josep M Ramón Torrell; María A Pérez-Cobaleda; María E Núñez-Torrón; Lydia Gorgojo; Magdalena García-Rodríguez; Rosa Díez-Díaz; Luis Armadans; Concepción Sánchez-Fernández; Teresa Mejías; Cristina Masuet; Rafael Pinilla; Nieves Antón; Pilar Segarra Journal: Hum Vaccin Immunother Date: 2013-01-16 Impact factor: 3.452